Emerging adenosine receptor agonists

Zhan-Guo Gao † & Kenneth A Jacobson
NIDDK, National Institutes of Health, Molecular Recognition Section, Laboratory of Bioorganic Chemistry, 9000 Rockville Pike, Bethesda, Maryland 20892-0810, USA

Adenosine receptors (ARs) are a four-member subfamily of G protein-coupled receptors and are major targets of caffeine and theophylline. There are four subtypes of ARs, designated as A₁, A₂A, A₂B, and A₃. Selective agonists are now available for all four subtypes. Over a dozen of these selective agonists are now in clinical trials for various conditions, although none has received regulatory approval except for the endogenous AR agonist adenosine itself. A₁ AR agonists are in clinical trials for cardiac arrhythmias and neuropathic pain. A₂A AR agonists are now in trials for myocardial perfusion imaging and as anti-inflammatory agents. A₂B AR agonists are under preclinical scrutiny for potential treatment of cardiac ischemia. A₃ AR agonists are in clinical trials for the treatment of rheumatoid arthritis and colorectal cancer. The present review will mainly cover the agonists that are presently in clinical trials for various conditions and only a brief introduction will be given to major chemical classes of AR agonists presently under investigation.

Keywords: adenosine receptor, agonist, cardiac arrhythmia, cardiac perfusion imaging, colon cancer, G protein-coupled receptor, inflammation, nucleoside, pain, rheumatoid arthritis

Expert Opin. Emerging Drugs (2007) 12(3):479-492

1. Background

Adenosine receptors (AR) are major targets of caffeine, theophylline and other methylxanthines, which are natural antagonists of ARs. Adenosine is the major endogenous agonist, although its metabolite, inosine, can also activate some subtypes of ARs.

The biologic action of adenosine was first identified in the cardiovascular system by Drury and Szent-Gyorgyi [1], who reported the effect of adenosine on heart rate, atrioventricular conduction and blood pressure. Since then adenosine has been reported to play a role in numerous tissues mainly through four subtypes of ARs (A₁, A₂A, A₂B, and A₃), which are cell surface receptors containing seven transmembrane domains and couple to intracellular GTP binding proteins. Evidence of the role of adenosine in the brain was mainly postulated pharmacologically based on the effects of methylxanthines, such as caffeine and theophylline [2-4].

AR signaling has been extensively studied [5-7]. A₁ and A₃ ARs primarily couple to the G₁₁0 proteins, which mediate the inhibition of adenylyl cyclase, and A₂A and A₂B ARs couple to G₄ proteins, which activate adenylyl cyclase. In addition, the A₂B AR couples to G₁₁₁ proteins, which stimulate phospholipase C activity and subsequently the protein kinase C activity and intracellular calcium mobilization. In addition to the activation of Gα subunits, ARs also stimulate the activity of Gβγ subunits, which induce the activation of numerous signaling pathways, such as phospholipase C, PKC, phosphoinositide 3-kinases, MAPKs and ion channels. All four subtypes of ARs may have a role in cell growth, death and differentiation [7].
ARs are widely distributed both in the brain and in peripheral systems [8,9]. In the brain, the A₁AR is widely expressed in many areas. Pre- and postsynaptic activation of the A₁AR inhibits synaptic transmission, in part by suppressing the release of excitatory transmitters [10]. The A₂₃AR is less widely expressed, with greatest density in the striatum, nucleus accumbens and olfactory tubercle. The A₂βAR and A₃AR are expressed at low density in most brain regions and are implicated in purinergic signaling in neuronal–glial interactions. ARs are also widely distributed in the autonomic and enteric nervous systems. Distribution of neural ARs in the human intestine has been investigated. Four subtypes of AR mRNAs are differentially expressed in neural and non-neural layers of the jejunum, ileum, colon and cecum [11]. In the bladder, A₁ARs are prominently localized to the apical membrane of the umbrella cell layer, whereas A₂β, A₂B and A₃ ARs are localized on the basolateral membrane of umbrella cells and the plasma membrane of the underlying cell layers. A₁, A₃A and A₂B ARs are all expressed on normal human airway smooth muscle cells, and both A₁ and A₂₃A ARs are expressed in vagal pulmonary C fibers. A₁ and A₂A ARs are highly expressed in gastric mucosa. A₂₃ARs are also widely distributed in the immune cells, such as T cells and macrophages. A₃ ARs are abundantly expressed in various blood cells, such as neutrophils and eosinophils. Various subtypes of ARs have also been detected in the heart, blood vessels, kidney and other organs throughout the body [8,9]. The wide and abundant distribution of these receptors suggests that they potentially play a critical role in the body and, thus, potentially useful therapeutic agents may be developed based on the AR distribution and AR function [12]. For example, the abundance of A₁ARs in the atrioventricular node of the heart is the basis for clinical development of selective A₁AR agonists as antiarrhythmic agents. The abundant A₂₃ARs in coronary blood vessels is the basis for the development of A₂₃AR selective agonists for cardiac perfusion imaging. The high-level expression of the A₃AR in neutrophils and eosinophils may give it a role in inflammation [13,14]. It should be noted that the distribution of ARs may be species dependent. For example, A₁ARs are rich in rat, but not human testes [8,15,16].

Genetic deletion of all four subtypes of ARs has been carried out and the resulting knockout mice are viable and lack of negative inotropic effects [20]. The pharmacologic profile indicates that the peripheral analgesic effect of adenosine is mediated by the A₁AR, and analgesia is lost in mice in which the A₁AR has been genetically eliminated [17]. Genetic knockout of the A₁AR in mice removes the discriminative-stimulus effects, but not the arousal effect of caffeine [21]. Genetic knockout of the A₁AR also increases anxiety and hyperalgesia [17]. Study of A₂₃AR knockout mice reveals functional interaction between the spinal opioid receptors and peripheral ARs. A₁AR knockout mice demonstrate a decreased, whereas A₂₃AR null mice demonstrate an increased, thermal threshold to noxious heat stimulation, supporting an A₁AR-mediated inhibitory and A₂₃AR-mediated excitatory effect on pain transduction pathways [21]. Knockout of the A₂₃AR, but not the A₁AR, eliminates the arousal effect of caffeine [18,22]. Genetic knockout of the A₂₃AR also suggests a link to increased anxiety and protection against the damaging effects of ischemia and the striatal toxin 3-nitropropionic acid. Studies on A₂βAR knockout mice suggested that the A₂βAR may have both pro- and anti-inflammatory roles [19,23,24]. The importance of A₂βAR in the brain still awaits future investigation. Genetic knockout of the A₁AR leads to increased neuronal damage in a model of carbon monoxide-induced brain injury [25]. Neutrophils lacking A₂ARs show correct directionality, but diminished speed of chemotaxis [13].

Due to the wide distribution and extensive and complex signaling coupling nature in the body, ARs are involved in a large variety of physiologic and pathophysiologic events. Numerous agonists of ARs are under development for potential therapeutic applications and some are already in the late phases of clinical trials [9,12,26], although none has yet received regulatory approval except for adenosine itself. The present review will mainly describe various agonists under clinical trials for various diseases. Major chemical classes of AR agonists presently under investigation will only be introduced briefly.

2. Medical need and existing treatment

Over a dozen AR agonists are now in clinical trials for various diseases. These agonists are primarily being developed for the following conditions: cardiac arrhythmias, neuropathic pain, myocardial perfusion imaging, inflammatory diseases and colon cancer [12,26]. The rest of this section will briefly discuss the medical need and major existing treatment of these conditions.

2.1 Cardiac arrhythmias

In clinical practice, among the most frequently encountered cardiac arrhythmias are atrial fibrillation (AF), supraventricular arrhythmias, paroxysmal supraventricular tachycardia (PSVT) and atrial flutter. Approximately 6 million people worldwide experience AF, a condition in which the heart beats at 2 – 3-times its normal rate [27]. Although AF is the most common of these arrhythmias, PSVT is also a relatively frequent occurrence with ~ 89,000 new cases being diagnosed on an annual basis [28]. Overall, it is estimated that PSVT is present in 570,000 individuals and accounts for ~ 30,000 hospitalizations in the US [28].

At present, available therapeutic agents for PSVT include adenosine, non-dihydropyridine calcium channel blockers (e.g., diltiazem or verapamil) or β-blockers. Adenosine is preferred over the other atrioventricular nodal blockers primarily because of its more rapid onset, shorter half-life and lack of negative inotropic effects [29]. Adenosine is similarly potent at A₁, A₂A and A₃, but weak at the A₂β AR. Its therapeutic effects in terminating PSVT are mediated by its actions at the A₁ AR, whereas its adverse effects most
likely result from its non-selective activation of the other ARs [30]. Despite its efficacy in the treatment of PSVT, the use of adenosine can be limited by adverse effects such as flushing, dyspnea, chest discomfort and hypotension [31]. In addition, adenosine has been shown to promote the development of AF in ≤ 15% of patients [32]. Although these adverse effects are usually transient in duration because of the short half-life of adenosine, there has been interest in developing a selective A1AR agonist that would have minimal side effects [33].

2.2 Neuropathic pain
There are already three recent reviews in this journal specifically describing the medical need and the present treatment of neuropathic pain [34-36], thus, only a brief introduction will be given here. Unlike inflammatory pain, which can be adequately managed in the clinic, neuropathic pain is typically unresponsive to conventional analgesics, such as opioids, COX-2 inhibitors and NSAIDs. The presently available treatments for neuropathic pain include: antidepressants, anticonvulsants and opioids [35,36]. Drugs from the above-mentioned classes only showed moderate relief in < 50% of the treated patients. In addition, undesirable side effects of these drugs are common. Thus, there remains a clear medical need for novel classes of drugs with higher efficacy and reduced side effects.

2.3 Myocardial perfusion imaging
Myocardial perfusion studies use either physical exercise or pharmacologic vasodilator stress to induce maximum myocardial hyperemia. At present, pharmacologic stress is being performed with increasing frequency over exercise stress. Although exercise remains the preferred modality of stress testing, many patients are limited from completing a maximum stress test for a variety of reasons. Presently, almost 50% of myocardial performance index (MPI) performed in the US is done with pharmacologic stress testing [37]. At present, there are two classes of pharmacologic stressing agents used in the clinic: coronary vasodilating agents such as adenosine and dipyridamole; and positive inotropic and chronotropic agents that increase cardiac workload and potentially cause myocardial ischemia, such as catecholamines (dobutamine). Dipyridamole and adenosine have a high side effect profile, provide higher than needed coronary artery flow rates and use a relatively complicated method of administration. Adenosine not only activates A1 and A2ARs, but also non-selectively activates A1 and A3 ARs, which contributes to the many common and undesirable side effects of adenosine vasodilator stress (e.g., chest pain, dyspnea, severebronchoconstriction and atrioventricular conduction abnormalities). Thus, there is a clear need to develop new pharmacologic stressor agents that are simpler to administer, have an improved side effect profile and offer greater accessibility to patients who have contraindications to other agents [38].

2.4 Inflammation
The inflammation process involves a series of events that can be elicited by numerous stimuli, such as infectious agents and ischemia. Each type of stimulus provokes a characteristic pattern of response representing a relatively minor variation on a theme. The response is generally accompanied by the familiar clinical signs of erythema, edema, tenderness and pain. Uncontrolled inflammation plays an important role in the pathogenesis of major diseases including cancer, heart disease, atherosclerosis and sepsis [39,40]. Drugs used to control symptoms and signs of inflammation are generally classified as steroidal and NSAIDs. Steroidal drugs are known to be effective in many cases but they also produce considerable side effects especially during long-term application. Conventional NSAIDs showing therapeutic effects are often preferable. However, the effects of these drugs are often uncertain and they may also produce severe side effects.

Rheumatoid arthritis (RA) is a chronic, destructive inflammatory joint disease [41]. It leads to functional impairment in most patients and to severe disability in many. Prognosis has improved in recent years because of the availability of new biologic therapies and management strategies. The plethora of available treatments provides a challenge for rheumatologists to choose the most appropriate therapy for each individual patient. The efficacy of a treatment regimen is the most important factor to consider, as only in those regimes with convincing efficacy are considerations of safety and cost meaningful. The primary question in clinical practice will, therefore, be the likelihood and degree of clinical response to different therapies.

Although the pathogenesis of RA is largely unknown, it appears to be an autoimmune disease driven primarily by activated T cells, giving rise to T-cell-derived cytokines, such as IL-1 and TNF. Many cytokines, including IL-1 and TNF, have been found in the rheumatoid synovium. The drugs available at present include steroids, which are known to interfere with the synthesis and/or actions of cytokines, and COX inhibitors such as aspirin, ibuprofen and diclofenac, which presumably inhibit the synthesis of prostaglandins. However, the therapeutic effects of these drugs are often uncertain and side effects such as gastric and intestinal ulceration are common. Thus, there is still a clear need to develop novel and more effective NSAIDs.

2.5 Colorectal cancer
Colorectal cancer is one of the world’s most common cancers. It is the second leading cause of death due to cancer in the US with a 6% personal lifetime risk, > 130,000 case/year and > 48,000 deaths expected in 2001 [42]. Colorectal cancer incidence and mortality rates increase with age, sharply so after age 60. Diagnostic stage determines survival: patients with lesions that are confined to the colonic wall have a 75% probability of surviving for 5 years, whereas those with distant metastases have only a 5 – 10% probability of living for 5 years. Unfortunately, most colorectal cancers are
recognized after regional or distant metastasis has occurred. There are limited treatment options for advanced disease, but favorable survival chances for early disease, so in addition to detection at an early stage, the prospects for control of colorectal cancer rest in early surgery and the development of novel and more effective therapeutic agents.

3. Adenosine receptor agonist class review

Most AR agonists have been adenosine derivatives thus far. Adenosine derivatives have been developed as both non-selective AR agonists and selective agonists for A₁, A₂A and A₃ ARs [9,12,26]. Generally, these agonists are substituted at 2-,5′- or N⁶-positions of adenosine. However, it was found that, in addition to the 5′-substitution, the ribose moiety could also be replaced with a methanocarba and the 4′-oxygen could be replaced with a thio group [43,44]. Adenosine derivatives selective for A₁, A₂A and A₃ ARs have been extensively used as pharmacologic tools and many of them are commercially available. Selective agonists for the A₁AR include: CPA, CCPA, CHA and (S)-ENBA. CPA, CCPA and CHA are very selective at the murine A₁AR. For all drug names in full, see Box 1. At human A₁AR, they only show a modest selectivity (10 – 30-fold over A₂AR) [45,46]. (S)-ENBA is selective for the A₁AR in both humans and rats [45]. CGS21680 and DPMA are selective at the murine, but not the human, A₂A AR, and they are also fairly potent at the human A₁AR [45]. NECA has been used to study the A₂BAR, although it is non-selective. A series of NECA derivatives has recently been reported to be modestly A₂BAR selective [47] as measured with a cyclic AMP assay at the A₂BAR and binding assays at other AR subtypes. However, the selectivity has not been determined with a similar assay system at all four AR subtypes. IB-MECA and CI-IB-MECA are potent at both human and rat A₂ARs [45,48], but a certain degree of species-dependent selectivity may also be found.

In addition to adenosine, inosine has also been reported to be an agonist of ARs, although shown to be weaker than adenosine in rats. Inosine binds to the A₁AR and stimulates mast cell degranulation. Inosine lowers cyclic AMP in HEK-293 cells expressing rat A₁ARs with an EC₅₀ of 12 μM and stimulates rat basophilic leukemia (RBL)-2H3 rat mast-like cell degranulation with an EC₅₀ of 2.3 μM [49]. It was found later that inosine is more potent for human A₂AR, although it only shows partial maximal agonist efficacy [9]. The potency, maximal agonist efficacy and selectivity of inosine derivatives as agonists for the ARs have not been extensively explored.

Several classes of non-nucleoside agonists have also been reported recently. The first highly potent agonist for the A₂BAR is actually a non-nucleoside agonist [50,101,102]. Based on the structure–activity relationship studies, the first selective A₂BAR agonist, BAY-60-6583 [51-53], has been developed. This class of compounds was also to display a remarkable agonistic–antagonistic profile at the A₁AR [54]. Selective agonists for A₂A and A₃ ARs from this class of compounds have not been reported so far.

Müller and colleagues also reported another two classes of non-adenosine compounds as agonists for ARs, although they only showed micromolar potency. Lignans isolated from Valériana have been reported to be partial agonists for the A₁AR [55]. Some amino acid derivatives are reported to be weak partial agonists of A₁ and A₃ ARs [56].

In addition to directly acting agonists, allosteric modulators for ARs have also been developed. PD81,723 and T62 are allosteric enhancers of the A₁AR function [57]. DU124,183 and LUF6000 are allosteric enhancers of the A₂AR function [58].
4. Current research goals

Briefly, the major research goals currently are to understand more about the functions of the AR subtypes in the body and to develop more potent and selective agonists for an individual AR subtype independent of species. With the availability of knockout animals and selective agonists for all AR subtypes, especially the recent availability of the A2B AR knockout animals and A2B AR selective agonists [19,52], it is expected that many ambiguous roles of individual AR subtypes will be clarified in the near future. This will further help the rational clinical development of AR agonists.

5. Scientific rationale and the development of adenosine receptor agonists for various conditions

5.1 Cardiac arrhythmia

One of the original findings of the biologic functions of adenosine by Drury and Szent-Gyorgyi [1] is its effect on heart rate. Thus, the potential therapeutic effect of adenosine for cardiac arrhythmias has been a long-term area of investigation. Intravenous infusion of adenosine has been found to restore normal heart rhythm in patients with paroxysmal supraventricular tachycardia (PSVT) [12,26]. Although adenosine is preferred over other atrioventricular nodal blockers due to its more rapid onset, shorter half-life and lack of negative inotropic effects, the use of adenosine can be limited by side effects such as flushing, dyspnea, chest discomfort and hypotension [31]. It is now known that the A1 AR is abundant in the atrioventricular node of the heart and the effect of adenosine on heart rhythm is mainly through activation of the A1 AR [33]. Thus, selective A1 AR agonists are needed to avoid side effects related to other AR subtypes.

Tecadenoson (CVT-510) is a novel A1 AR agonist under development for the treatment of PSVT, AF and atrial flutter [33]. In Phase III clinic trials it effectively terminated PSVT. Compared with other antiarrhythmic agents on the market, it appeared to have minimal cardiac side effects, such as blood pressure and atrioventricular nodal conduction during sinus rhythm, at low doses. However, at higher doses, it also caused high-degree atrioventricular block. Thus, the use of full agonist tecadenoson as antiarrhythmic agents may be limited by their ability to cause high-degree atrioventricular block and profound bradycardia and AF. Thus, the partial agonist for the A1 AR, CVT-2759, has been developed, which in guinea-pig heart appears to be useful to slow atrioventricular nodal conduction and thereby ventricular rate without causing second-degree atrioventricular block, bradycardia, atrial arrhythmias or vasodilation [59,60]. However, the clinical trial data of CVT-2759 has not been available so far. N6-cyclopentyl-5′-((N-ethyl)carboxamido)adenosine (selodenoson) is a selective A1 AR agonist whose Phase II clinical trials has been completed for patients with AF [201]. Although several A1 AR agonists are in development, it is

suggested that selodenoson may be the only one that can effectively be formulated for intravenous administration to control heart rate during acute attacks and for oral administration for the chronic management of AF [104].

The pharmaceutical formulation for controlled release of selodenoson has been reported in 2005 [104].

5.2 Neuropathic pain

A1 AR agonists reduce pain signaling in the spinal cord where the receptors are highly expressed. The A1 AR activation produces inhibitory effects on pain in a number of preclinical models and is a focus of attention. In humans, intravenous infusions of adenosine reduce some aspects of neuropathic pain and can reduce postoperative pain mainly through the A1 AR. It has been shown that mice lacking A1 ARs exhibited moderate hyperalgesia to heat stimulation [17], whereas mice lacking A2A AR were shown to be hypoalgesic, probably reflecting a peripheral pronociceptive function [18]. Increased nociceptive response in mice lacking the A1 AR has been observed [61]. Thus, it is suggested that selective A1 AR agonists may be tested clinically as analgesics, particularly under conditions of neuropathic pain.

In addition to directly acting A1 AR agonists, allosteric enhancers of the A1 AR function are also of potential interest for the treatment of neuropathic pain. It has been shown in a GTPγS saturation analysis that an allosteric enhancer T62 increased the number of G proteins activated by agonist, but had no effect on the affinity of activated G proteins for GTPγS. [35S]GTPγS autoradiography showed that the neuroanatomical localization of T62-stimulated [35S]GTPγS binding was identical to that of A1 AR agonist phenylisopropyladenosine (PIA)-stimulated activity. The increase in PIA-stimulated activity by T62 varied between brain regions, with areas of lower A1 AR activation producing the largest per cent modulation by T62. These results suggest a mechanism of allosteric modulators to increase the number of activated G proteins per receptor and provide a neuroanatomical basis for understanding potential therapeutic effects of such drugs [62].

A selective A1 AR agonist, GR-79236, has been in clinical trial for the treatment of pain, however, it was discontinued probably due to cardiovascular side effects. Phase II clinical trials of another A1 AR agonist, GW-493838 (structure not disclosed) is now under phase II clinical trials for the treatment of pain, however, it was discontinued probably due to cardiovascular side effects. Phase II clinical trials of another A1 AR agonist, GW-493838 (structure not disclosed), for the treatment of neuropathic pain has been completed [202]. However, it seems that the further development of GW-493838 has also been discontinued. The A1 AR-selective allosteric enhancer T-62 was also shown to reduce hypersensitivity in carageein-inflamed rats by a CNS mechanism. Phase I clinical trials of T62 have been completed as a treatment for neuropathic pain. The A2A AR agonist BVT.115959 (structure not disclosed) is now under Phase II clinical trials for diabetic neuropathic pain [105,203]. A1 and A2A ARs are widely distributed in the brain and spinal cord and represent a non-opiate target for pain management. Activated spinal A1 ARs inhibit sensory transmission by
Emerging adenosine receptor agonists

inhibiting the slow ventral root potential, which is the C-fiber-evoked excitatory response associated with noception. Additionally, adenosine is also being tested in Phase II clinical trials for perioperative pain [204]. At least 50 new molecular entities have reached clinical development for neuropathic pain, which include glutamate receptor antagonists, cytokine inhibitors, opioids, cannabinoids, COX inhibitors and AR agonists. At present, eight drugs are in Phase III clinical trials for neuropathic pain [36].

5.3 Cardiovascular imaging

In addition to the effect of adenosine on heart rate, another prominent cardiovascular effect is its vasodilatory effect. Adenosine and dipyridamole are presently used in clinic as pharmacologic stress agents for cardiovascular imaging [37,63]. It is now known that this vasodilatory effect is mainly through the A<sub>2A</sub>AR, which is abundant in coronary blood vessels. Thus, AR agonists selective at the A<sub>2A</sub>AR are needed for this purpose.

Based on preclinical animal work, three selective A<sub>2A</sub>AR agonists, regadenoson, binodenoson and apadenoson, have been in Phase III studies as pharmacologic stress agents. For single-photon emission computed tomography imaging, binodenoson and regadenoson were concordant with adenosine images for detection and quantitation of ischemia. Despite the high A<sub>2A</sub>AR selectivity of binodenoson and regadenoson in preclinical studies, subjective side effects attributable to other AR subtypes were still observed in human studies and although they are slightly lower than adenosine. Apadenoson was reported to be more selective than the other two agonists that entered Phase III trials earlier. It remains to be seen whether or not approval of regadenoson and binodenoson by the FDA will translate into first-to-market advantages. It is reported that a comparison study of apadenoson and adenosine with treadmill exercise stress has been terminated. A study to examineMPI single photon emission computed tomography (SPECT) imaging with apadenoson and adenosine compared with coronary angiography has also been terminated [205]. The Phase II optimization study of apadenoson and sestamibi planar imaging has been completed [205].

5.4 Inflammation

Adenosine is a ubiquitous molecule that influences every physiologic system studied thus far. Endogenous adenosine exerts a significant proportion of its anti-inflammatory actions by means of binding to A<sub>2A</sub>ARs found in almost all immune cells, including lymphocytes, monocytes, macrophages, human natural killer T cells and dendritic cells [64-66].

Adenosine acts non-selectively by reducing expression of adhesion molecules and release of pro-inflammatory mediators (e.g., reactive oxygen species, elastase and TNF-α). Selective A<sub>2A</sub>AR agonists have been developed [67,68] and shown to inhibit multiple manifestations of inflammatory cell activation including production of superoxide, nitric oxide, TNF-α, IL-12, IL-10 and VEGF [69]. A<sub>2A</sub>AR agonists are also vasodilators, but the inhibition of inflammation occurs at low doses that produce few or no cardiovascular side effects. Through A<sub>2A</sub>AR activation, adenosine can inhibit T-cell activation, proliferation, and production of inflammatory cytokines and enhance the production of anti-inflammatory cytokines. Therefore, the selective A<sub>2A</sub>AR agonists hold significant potential in the treatment of inflammation.

Unlike the anti-inflammatory role of the A<sub>2A</sub>AR, the role of the A<sub>3</sub>AR and A<sub>1</sub>ARs as to pro-inflammatory or anti-inflammatory is still controversial (e.g., agonists have been found to be pro-inflammatory and anti-inflammatory, and there is evidence for an anti-inflammatory effect of A<sub>2B</sub> and A<sub>3</sub>AR agonists [20,23]). Adenosine augments IL-10 production by macrophages through an A<sub>2B</sub>AR-mediated post-transcriptional mechanism [70]. Adenosine inhibits TNF-α release from mouse peritoneal macrophages by means of A<sub>2A</sub> and A<sub>2B</sub>, but not the A<sub>1</sub>AR [71]. It is suggested that the pro- or anti-inflammatory roles of A<sub>3</sub> and A<sub>1</sub>ARs might depend on tissues, inflammatory stages and types.

Both A<sub>2A</sub> and A<sub>3</sub> AR agonists have been proposed for the treatment of rheumatoid arthritis. The rationale for this is likely at least in part due to their modulatory effects on TNF-α and NF-kB. It is known that TNF inhibitors have changed the therapeutic standard of treatment for patients with rheumatoid arthritis. The activation of A<sub>2A</sub>, A<sub>2B</sub> and A<sub>3</sub>ARs are involved in the inhibition of TNF and NF-kB, which could be a potential mechanism for the anti-inflammatory, especially the antirheumatic, effect of these ARs. However, the exact scientific or clinical rationale has not been clear so far. It has been suggested that both A<sub>2A</sub> and A<sub>3</sub> ARs are required for inhibition of inflammation by methotrexate and its analog MX-68 [72], and stimulation of AR subtypes A<sub>3</sub> and A<sub>2A</sub> may be a strategy worthy of further evaluation for the abrogation of acute or chronic inflammatory disorders [73]. Additionally, it is suggested that NF-kB is involved in regulating the level of A<sub>3</sub>ARs overexpressed in peripheral blood mononuclear cells in a RA model [74]. Anti-inflammatory effect of A<sub>1</sub>AR agonists have also been demonstrated in murine autoimmune arthritis models [75].

An A<sub>2A</sub>AR agonist, GW328267, designed for intranasal administration, has been in Phase II clinical trials for upper respiratory inflammatory disease, chronic obstructive pulmonary disease and asthma; however, the results at the dose used were negative and the compound has been withdrawn from clinical testing. MRE-0094 is in Phase II clinical trials for chronic, neuropathic and diabetic foot ulcers, due to the anti-inflammatory and wound healing effects of A<sub>2A</sub>AR agonists [76,206]. Clinical trials of ATL146e as an anti-inflammatory agent have also been initiated.

The A<sub>2A</sub>AR has long been proposed to be effective in the treatment of arthritis, however, clinical trial data have not been available so far. The A<sub>1</sub>AR agonist IB-MECA is an oral drug that has been successfully used in animal models and human Phase II RA trials to test the concept of targeting the A<sub>1</sub>AR for the treatment of inflammatory diseases. Phase I
studies in healthy volunteers, as well as the Phase IIa clinical studies in RA human patients have demonstrated this drug to have a favorable safety profile. Recent interim analysis of Phase IIa pilot study data indicates that CF101 has disease-modifying anti-inflammatory activity in RA patients failing methotrexate therapy. Can-Fite is now completing Phase IIb clinical trials of CF101 in RA. CF502, a more selective A₂AR agonist, is in preclinical development for RA [97,98]. Additionally, Can-Fite is about to initiate a Phase II clinical trial with CF101 for the treatment of psoriasis.

In the US, six biologic agents have been approved for the treatment of patients with RA [77]. However, it is not clear about the data on the comparative efficacies of the biologics, the appropriate sequencing of agents, the best cotherapies or the possible combined or staggered use of biologics marketed by different companies.

5.5 Cancer

There are several lines of evidence to show that AR agonists may induce, as well as protect, cell death depending on cell types. There has been evidence to suggest that some adenosine analogs may be potentially used for cancer therapy. Cisplatin and cordycepin are used in the clinic for the treatment of leukemia, although presumably not through AR activation.

Kohno et al. [78] found that two synthetic adenosine analogs IB-MECA (30 and 60 µM) and CI-IB-MECA (10 – 30 µM), but not CPA, CGS21680 and NECA ≤ 30 µM, induced apoptosis in HL-60 human promyelocytic leukemia cells. However, it was found later that low concentrations of the A₃ AR agonist CI-IB-MECA (10 nM or 1 µM) actually protected against apoptosis in HL-60 cells induced by a selective A₂AR antagonist (MRS1191), suggesting that apoptosis in HL-60 cells induced by adenosine analogs are not through the A₂AR or opposing effects can occur at different levels of receptor stimulation. This is consistent with the results from Gao et al. [79] with RBL-2H3 mast-like cells. The selective A₃ AR agonist, IB-MECA (10 nM and 1 µM), but not CPA and CGS21680 (100 nM), significantly protects apoptosis caused by exposure of RBL-2H3 cells to UV light. Lu et al. [80] also found that the adenosine analog, IB-MECA, indeed downregulates estrogen receptor α and suppresses human breast cancer cell proliferation, but not through an A₂AR-mediated mechanism, as low concentrations of IB-MECA did not inhibit cell death and selective A₃ AR antagonists did not affect the effect of IB-MECA. Kim et al. [81] found that CI-IB-MECA at the concentration of 30 µM, but not lower, induced apoptosis in HL-60 cells, but a corresponding (n)-methanocarba agonist, known to be equipotent to CI-IB-MECA at the A₂AR, did not. Lee et al. [82] have shown that a novel adenosine analog, thio-CI-IB-MECA, induces G₂/M/G₁ cell cycle arrest and apoptosis in human promyelocytic leukemia HL-60 cells also not by means of the A₂AR. The above results clearly suggested that inhibition of cell growth by high concentrations of A₃ AR agonists is not through an A₂AR-mediated mechanism, but the A₃ AR agonists induced protective effects are A₂AR-mediated. From this point of view, A₃ AR antagonists are potentially useful for certain types of cancers, but this has to be tested in various animal models. A₂AR antagonists have been proposed to be used as both antitumor agents and for treating inflammatory disorders such as RA [103].

By studying the role of the A₃ AR in various cell lines Borea and colleagues suggested that the A₃ AR may mediate both cell growth and cell death [83]. For example, the A₃ AR mediates a cell survival signal in A375 human melanoma cells [84], but it also inhibits cell proliferation by means of phosphatidylinositol 3-kinase/Akt-dependent inhibition of the extracellular signal-regulated kinase 1/2 phosphorylation in A375 human melanoma cells [85]. In colon cancer cell lines, endogenous adenosine, through the interaction with A₃ ARs, mediates a tonic proliferative effect [86]. It has been found that, in patients with colorectal cancer, overexpression of ARs in tumors was reflected in peripheral blood cells, and thus, the A₃ AR has been proposed to be potentially used as a diagnostic marker or a therapeutic target for colon cancer [87].

Fishman et al. [88] found that adenosine and other low molecular weight factors released by muscle cells inhibit tumor cell growth. It was found in a later study that at a relatively low concentration only IB-MECA, but not CPA and DPMA, induced inhibition of the growth of Nb2-11C rat lymphoma cell line [89]. In addition, the inhibitor effect of 25 µM adenosine can be blocked by an AR antagonist MRS1220 (0.1 µM) [89]. However, it should be noted that MRS1220 does not block the rat A₂AR at 0.1 µM, although it can block the rat A₃ AR at this concentration.

Mechanistic studies of the A₃ AR agonists, IB-MECA (CF-101) and CI-IB-MECA (CF-102) have also been performed in various cell types. Evidence has been presented for the involvement of Wnt signaling pathway in IB-MECA-mediated suppression of melanoma cells [90]. Inhibition of primary colon carcinoma growth and liver metastasis by the A₃ AR agonist CF101 have been described [91]. It has also been shown that IB-MECA inhibits colon carcinoma growth in mice by means of modulation of GSK-3β and NF-kB [92]. Evidence has also been shown that CF101 enhances the chemotherapeutic effect of 5-fluorouracil in a colon carcinoma murine model [93] and induces G-CSF production by means of NF-kB activation to produce myeloprotective effect [94]. The A₃ AR is shown to be highly expressed in tumor versus normal cells, suggesting a potential target for tumor growth inhibition [95]. However, it is not clear if the A₃ AR overexpression is a reason for or a result of cancer.

Although it has been suggested that A₃ AR agonists may produce a dual effect on tumor and normal cell growth, these studies have not been performed in parallel with normal and tumor tissues. It is also not clear if the behavior of the A₃ AR activation will be similar or different in vitro and in vivo.
Figure 1. Structures of adenosine receptor agonists in clinical trials for various conditions*.

*Structures of GW493838 and BVT.115959 not disclosed.
Table 1. Binding affinity or functional potency of selected agonists in clinical trials at four subtypes of adenosine receptors (EC_{50} and K_{i}, nM).

| AR agonists                        | Potency at ARs | Diseases                       | Development stages |
|------------------------------------|----------------|--------------------------------|--------------------|
| Adenosine (Adenocard, adenoscan)   | 310            | 700 24,000 290                 | PSVT; cardiac imaging Marketed |
| Selodenoson (DTI0009)             | 1.1           | 306 ND ND ND 903              | AF II              |
| Tecadenoson (CVT-510)             | 6.5           | 2320 ND ND ND                 | PSVT III           |
| CVT-2759                           | 180           | ND ND ND ND ND              | AF or PSVT ND      |
| Binodenoson (MRE0470)             | 48,000         | 270 430,000 903              | Cardiac imaging III |
| Apadenoson (ATL-146e)             | 77            | 0.5 ND ND ND 45              | Cardiac imaging III |
| Regadenoson (CVT-3146)            | > 10,000       | 290 > 10,000 > 10,000        | Cardiac imaging III |
| MRE0094                           | > 10,000       | 59 > 10,000 ND 1.4           | Diabetic foot ulcers II |
| BAY-60-6583                        | > 10,000       | > 10,000 ND 1.8              | Rheumatoid arthritis II |
| CF101 (IB-MECA)                   | 51            | 2900 11,000 1.4              | Rheumatoid cancer ND |
| CF102 (CI-IB-MECA)                | 220           | 5360 > 10,000 0.29           | Rheumatoid arthritis ND |
| CF502 (MRS3558)                   | 260           | 2300 > 10,000 0.29           | Rheumatoid arthritis ND |

* Rat.  ‡ Pig.  Data for BVT.115995 and GW493838 are not available. An A_{2A} AR agonist BVT.115995 is in Phase II clinical trials for diabetic neuropathic pain. Phase II trials of GW493838 for the treatment of neuropathic pain has been completed. T62 is an allosteric enhancer of the A_{1A} AR. For more information related to AR agonist potency and selectivity, see references [9,12,26,52,54].

AF: Atrial fibrillation; AR: Adenosine receptor; ND: Not determined or not disclosed; PSVT: Paroxysmal supraventricular tachycardia.

in humans and in animals. Given that the anticancer effect of A_{3} AR agonists is convincingly demonstrated, IB-MECA and CI-IB-MECA (with highly oral bioavailability) may represent a novel family of anticancer agents.

IB-MECA has been in Phase II clinical trials for colorectal cancer. CI-IB-MECA (CF102), a similar compound in its biologic properties to IB-MECA, is planned for use in cancer therapy in combination with chemotherapeutic drugs. Clinical studies carried out with CF101 that include some pilot studies in cancer patients, as well as extensive preclinical work, provide a rationale for use of CF102 in cancer therapy in combination with chemotherapy.

The structures of AR agonists presently in clinical trials are shown in Figure 1. The potencies of the AR agonists for four subtypes, their development stages and disease targets are listed in Table 1.

6. Potential development issues

Although selective agonists are available for all four subtypes, selectivity of some compounds for certain AR subtypes are still limited. Thus, potential side effects due to activation of AR subtypes other than the intended target are still possible.

Species-dependence for AR agonists is still a problem for the clinical development. This includes problems arising from studies using small animals if receptor homologs differ in pharmacology or same receptor function related to different subtypes in different species. For example, human and rat A_{3} ARs only share 72% overall identity of amino acids and A_{3} ARs are abundant in the rat, but not human testis. Mast cell degranulation is induced by the A_{2B} AR in dogs and humans, but by the A_{3} AR in mice. Thus, it can be speculated that some of the functions observed with one animal model may not be the case in other animal models and in humans. Cross-species testing systems are necessary to validate the receptor function or effects of agonists.

Another issue that should be noted is the pharmacokinetics of these agonists. Most AR agonists contain a ribose, which make these drugs hydrophilic. Thus, the penetration of these drugs to the CNS through the blood–brain barrier can be problematic. Of course it can also be argued that this property is advantageous if peripherally targeted. Adenosine itself can be transported by means of adenosine transporters, it is not clear if these transporters are permissible to other AR agonists.

In the clinical development of adenosine derivatives as AR agonists, one important aspect to be considered is that these agonists are nucleosides, which may interfere with nucleoside metabolism in the cells. For example, some selective A_{1} AR agonists are 5’-unmodified adenosines, which could be phosphorylated by adenosine kinases and then by nucleotide kinases and subsequently be incorporated into DNA or become agonists of P2Y receptors, the activation of which may induce different pharmacologic consequences. Also, the
stability of some compounds, such as ATL-146e, which is an ester derivative, could also be a development issue.

Additionally, as caffeine and theophylline are natural antagonists of ARs and are commonly consumed, the simultaneous antagonism should be considered when AR agonists are in clinical trials.

7. Expert opinion

With the availability of both selective agonists and genetic knockout animals for all four AR subtypes, it is expected that numerous roles of ARs that used to be ambiguous will be clarified in the near future. Also, with the identification of non-adenosine AR agonists, more selective and specific agonists for a certain subtype of ARs will hopefully be available. These agonists may show improved chemical and physical properties as drugs.

Adenosine itself is used under the name of Adenocard for controlling PSVT by activating the A1AR, and under the name of Adenoscan for myocardial perfusion imaging by activating the A2AAR. Despite its non-selective action, adenosine only shows moderate side effects due to its extremely short half-life (within seconds). The development of selective agonists for these purposes should be encouraging as they may exhibit reduced side effects. However, it should also be noted that the half-life of these synthesized agonists may be significantly longer than that of adenosine. Also, the presently available A1 and A2A AR agonists in clinical trials are only relatively selective. Both the longer half-life and the lack of absolute selectivity may contribute to additional side effects.

The A1AR could be a promising target for neuropathic pain. Phase II clinical trials of GW-493838 as an A1AR agonist for neuropathic pain have been completed. However, the next generation of A1AR agonists for neuropathic pain have not been reported. It is assumed that the non-adenosine A1AR agonists could be further clinically developed for neuropathic pain and other conditions.

Several A2AAR agonists are in trials as anti-inflammatory agents and for myocardial perfusion imaging. Compounds showing uncertain stability and lack of high selectivity may be useful for myocardial perfusion imaging and for external applications, such as diabetic foot ulcer and skin wound healing, but may not be suitable for anti-inflammatory agents administered orally or intravenously, as a long-term and lasting effect is needed. The A2AAR agonists have shown robust immunosuppressive effect and tissue protective action as well. Thus, selective A2AAR agonists could be promising agents for induction therapy in organ transplantation. Additionally, it is now known that both the sleep-promoting effect of adenosine and the arousal effect of caffeine are through the A2AAR, thus, the development of an A2AAR selective agonist that could penetrate the blood–brain barrier and produce minimal peripheral side effects would be extremely attractive. However, it should be noted that although the sleep-promoting effect of adenosine in rodents appears to be due to the A2AAR activation, there is an ongoing debate as to whether or not in humans the A1AR may be more important. A recent positron emission tomography study has shown that sleep deprivation increases A1AR binding in the human brain [96].

There will be new momentum in the A2BAR field, as both selective agonists and knockout mice are only recently available. Thus, some of the ambiguous AR functions, such as pro- and anti-inflammatory effects, ischemic protection and vasodilation need to be further clarified with these tools. One of the potent and selective non-adenosine A2BAR agonists, BAY-60-6583, has been shown to be effective in reduction of the infarct size by application after the onset of cardiac ischemia in a rabbit infarct model. Selective agonists for A2A and A1ARs could be potentially developed from non-adenosine agonists, which may show less species difference than nucleoside analogs (unpublished observation).

The abundance of the A3ARs in inflammation-related blood cells, such as neutrophils and eosinophils, may suggest a role for the A3AR in inflammation. However, the pro- or anti-inflammatory role of the A3AR has to be further clarified. Nevertheless, preliminary clinical trial data suggest that the A3AR may be a new promising target for RA. Regarding the anticancer role of some nucleosides or the A3AR, it is still to be further investigated.

Acknowledgements

Supported by the National Institute of Health and the National Institute of Diabetes and Digestive and Kidney Intramural Research Program. The authors declare no conflict of interest.
1. DRURY AN, SZENT-GYORGYI A: The physiological activity of adenine compounds with especial reference to their action upon the mammalian heart. J. Physiol. (Lond.) (1929) 68:213-237.

2. SATTIN A, RALL TW: The effect of adenosine and adenosine nucleotides on the cyclic adenosine 3′,5′-phosphate content of guinea pig cerebral cortex slices. Mol. Pharmacol. (1970) 6:13-25.

3. DALY JW: Cyclic Nucleotides in the Nervous System, Plenum Press, New York (1977).

4. FREDHOLM BB: Are methylxanthines effects due to antagonism of endogenous adenosine? Trends Pharmacol. Sci. (1980) 1:129-132.

5. VAN CALKER D, MULLER M, HAMPRECHT B: Adenosine regulates via two different types of receptors, the accumulation of cyclic AMP in cultured brain cells. J. Neurochem. (1979) 33:999-1005.

6. LONDOS C, COOPER DM, WOLFF J: Subclasses of external adenosine receptors. Proc. Natl. Acad. Sci. USA (1980) 77:2551-2554.

7. SCHULTE G, FREDHOLM BB: Signalling from adenosine receptors to mitogen-activated protein kinases. Cell Signal (2003) 15:813-827.

8. DIXON AK, GUBITZ AK, SIRINATHSINGHJI DJ, RICHARDSON PJ, FREEMAN TC: Tissue distribution of adenosine receptor mRNAs in the rat. Br. J. Pharmacol. (1996) 118:1461-1468.

9. FREDHOLM BB, IJZERMAN AP, JACOBSON KA, KLOTZ KN, LINDEN J: International Union of Pharmacology, XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev. (2001) 53:527-552.

10. PASCUAL O, CASPER KB, KUBERA C et al.: Astrocytic purinergic signaling coordinates synaptic networks. Science (2005) 309:113-116.

11. CHRISTOFI FL, ZHANG H, YU JG et al.: Differential gene expression of adenosine A1, A2a, A2b, and A3 receptors in the human enteric nervous system. J. Comp. Neurol. (2001) 439:46-64.

12. JACOBSON KA, GAO ZG: Adenosine receptors as therapeutic targets. Nat. Rev. Drug Disc. (2006) 5:247-264.

13. CHEN Y, CORRIDEN R, INOUE Y et al.: ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors. Science (2006) 314:1792-1795.

14. LINDEN J: Cell biology, Purinergic chemotaxis. Science (2006) 314:1689-1690.

15. SALVATORE CA, JACOBSON MA, TAYLOR HE, LINDEN J, JOHNSON RG: Molecular cloning and characterization of the human A3 adenosine receptor. Proc. Natl. Acad. Sci. USA (1993) 90:10365-10369.

16. ZHOU QY, LI C, OLAH ME, JOHNSON RA, STILES GL, CIVELLI O: Molecular cloning and characterization of an adenosine receptor: the A3 adenosine receptor. Proc. Natl. Acad. Sci. USA (1992) 89:7432-7436.

17. JOHANSSON B, HALLDNER L, DUNWIDDIE TV et al.: Hyperalgesia, anxiety, and decreased hypoxic neuroprotection in mice lacking the adenosine A3 receptor. Proc. Natl. Acad. Sci. USA (2001) 98:9407-9412.

18. LEDENT C, VAUGEOS JM, SCHIFFMANN S et al.: Aggressiveness, hypalgesia and high blood pressure in mice lacking the adenosine A3 receptor. Nature (1997) 388:674-678.

19. YANG D, MCCRANN DJ, NGUYEN H et al.: The A3 adenosine receptor protects against inflammation and excessive vascular adhesion. J. Clin. Invest. (2006) 116:1913-1923.

20. SALVATORE CA, TILLEY SL, LATOUR AM, FLETCHER DS, KOLLER BH, JACOBSON MA: Disruption of the A3 adenosine receptor gene in mice and its effect on stimulated inflammatory cells. J. Biol. Chem. (2000) 275:4429-4434.

21. FREDHOLM BB, CHEN J, MASINO SA, VAUGEOS JM: Actions of adenosine at its receptors in the CNS: insights from knockouts and drugs. Ann. Rev. Pharmacol. Toxicol. (2005) 45:385-412.

22. HUANG ZL, QU WM, EGUCHI N et al.: Adenosine A2b, but not A1, receptors mediate the arousal effect of caffeine. Nat. Neurosci. (2005) 8:858-859.

23. SUN CX, ZHONG H, MOHSENIN A et al.: Role of A2b adenosine receptor signaling in adenosine-dependent pulmonary inflammation and injury. J. Clin. Invest. (2006) 116:2173-2182.

24. LINDEN J: New insights into the regulation of inflammation by adenosine. J. Clin. Invest. (2006) 116:1835-1837.

25. FEDOROVA IM, JACOBSON MA, BASILE A, JACOBSON KA: Behavioral characterization of mice lacking the A3 adenosine receptor: sensitivity to hypoxic neurodegeneration. Cell Mol. Neurobiol. (2003) 23:431-447.

26. YAN L, BURBIE JC, MAASS A, MüLLER CE: Adenosine receptor agonists: from basic medicinal chemistry to clinical development. Expert Opin. Emerging Drugs (2003) 8:537-576.

27. GOLDSTEIN RN, STAMBLER B: New antiarrhythmic drugs for prevention of atrial fibrillation. Prog. Cardiovasc. Dis. (2005) 48:193-208.

28. OREJARENA LA, VIDAILET H JR, DESTEFANO F et al.: Paroxysmal supraventricular tachycardia in the general population. J. Am. Coll. Cardiol. (1998) 31:150-157.

29. BLOMSTROM-LUNDQVIST C, SCHEINMAN MM, ALIOT EM et al.: American College of Cardiology; American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines. Writing Committee to Develop Guidelines for the Management of Patients with Supraventricular Arrhythmias. Circulation (2003) 108:1871-1909.

30. DHALLA AK, SHROYOCH JC, SHREENIWAS R, BELARDINELLI L: Pharmacology and therapeutic applications of A1 adenosine receptor ligands. Curr. Top. Med. Chem. (2003) 3:369-385.

31. HEBBAR AK, HUESTON WJ: Management of common arrhythmias: Part I. Supraventricular arrhythmias. Am. Fam. Physician (2002) 65:2479-2486.

32. STRICKBERGER SA, MAN KC, DAOUT EG et al.: Adenosine-induced atrial arrhythmias: a prospective analysis. Ann. Intern. Med. (1997) 127:417-422.

33. PETERMAN C, SANOSKI CA: Tecadenoson: a novel, selective A1 adenosine receptor agonist. Cardiol. Rev. (2005) 13:315-321.

34. WALLACE MC: Emerging drugs for neuropathic pain. Expert Opin. Emerging Drugs (2001) 6:249-259.

35. COLLINS SD, CHESSELL IP: Emerging therapies for neuropathic pain. Expert Opin. Emerging Drugs (2005) 10:95-108.
Emerging adenosine receptor agonists

36. GILRON I, CODERRE TJ: Emerging drugs in neuropathic pain. Expert Opin. Emerging Drugs (2007) 12:113-126.
37. HENDEL RC, JAMIL T, GLOVER DK: Pharmacologic stress testing: new methods and new agents. J. Nucl. Cardiol. (2003) 10:197-204.
38. CERQUEIRA MD: Advances in pharmacologic agents in imaging: new A2a receptor agonists. J. Am. Coll. Cardiol. Rep. (2006) 8:119-122.
39. SITKOVSKY MV, LUKASHEV D, APASOV S et al.: Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A3 receptors. Ann. Rev. Pharmacol. Toxicol. (2001) 41:775-787.
40. LINDEN J: Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection. Ann. Rev. Pharmacol. Toxicol. (2001) 41:775-787.
41. SMOLEN JS, ALETAHA D: Challenges of predicting treatment response in patients with rheumatoid arthritis. Nat. Clin. Pract. Rheumatol. (2005) 1:62-63.
42. SCHOEN RE: The case for population-based screening for colorectal cancer. Nat. Rev. Cancer (2002) 2:65-70.
43. JACOBSON KA, JIN X, SHEPHERD RK, DULING BR, et al.: N6-substituted D-4'-thioadenosine-5'-methylyuronamides: potent and selective adenosine receptor agonists. J. Med. Chem. (2003) 46:3775-3777.
44. GAO ZG, KIM SK, IJZERMAN AP, et al.: Synthesis and biological evaluation of novel 1-deoxy-1-[(hetero)arylcarbonyl] hydrazinolyl-9H-purin-9-yl-N-ethyl-β-D-ribofuranouronamide derivatives as useful templates for the development of Ad3b adenosine receptor agonists. J. Med. Chem. (2007) 50:374-380.
45. KIM HO, JI XD, SIDDIQI SM et al.: 2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A1 adenosine receptors. J. Med. Chem. (1994) 37:3614-3621.
46. JIN X, SHEPHERD RK, DULING BR, LINDEN J: Inosine binds to A3 adenosine receptors and stimulates mast cell degranulation. J. Clin. Invest. (1997) 100:2849-2857.
47. BEUKERS MW, CHANG LC, VON FRIJTAG DRABBE KUNZEL JK et al.: New, non-adenosine, high-potency agonists for the human adenosine A3 receptor with an improved selectivity profile compared to the reference agonist N-ethylcarboxamidoadenosine. J. Med. Chem. (2004) 47:3707-3709.
48. KRAHN T, ALBRECT B, ROSENTERRE U, COHEN MV, SOLENKOVA, DOWNEY JM: Adenosine A2B receptor agonist mimics postconditioning: characterization of a selective adenosine A2B agonist in a rabbit infarct model. Purinergic Signal. (2006) 2:105-106.
49. ECKLE T, KRAHN T, GRENZ A et al.: Cardioprotection by ecto-5'-nucleotidase (CD73) and A2B adenosine receptors. Circulation (2007) 115:1581-1590.
50. VERYARD C: Developments in adenosine receptor agonists for the human adenosine A3 receptor. Expert Opin. Investig. Drugs (2007) 16:1313-1319.
51. LAPPAS CM, SULLIVAN GW, LINDEN J: Adenosine A2A agonists in development for the treatment of inflammation. Expert Opin. Investig. Drugs (2005) 14:797-806.
52. LAPPAS CM, DAY YJ, MARSHALL MA, ENGELHARD VH, LINDEN J: Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation. J. Exp. Med. (2006) 203:2639-2648.
53. AKKARI R, BURBIEL JC, HOCKEWEYER J, MULLER CE: Recent progress in the development of adenosine receptor ligands as...
antinflammatory drugs. *Curr. Top. Med. Chem.* (2006) 6:1375-1399.

68. CRISTALLI G, CACCIARI B, DAL BEN D et al.: Highlights on the Development of \( A_2 \delta \) adenosine receptor agonists and antagonists. *Chem. Med. Chem.* (2007) 2:260-281.

69. HASKO G, PACHER P, DEITCH EA, VIZI ES: Shaping of monocyte and macrophage function by adenosine receptors. *Pharmacol. Ther.* (2007) 113:264-275.

70. NEMETH ZH, LUTZ CS, CSORA B et al.; Adenosine augments IL-10 production by macrophages through an \( A_2 \delta \) receptor-mediated posttranscriptional mechanism. *J. Immunol.* (2005) 175:8260-8270.

71. KRECKLER LM, WAN TC, GE ZD, AUCHHAM PAC J: Adenosine inhibits TNF-\( \alpha \) release from mouse peritoneal macrophages via \( A_2 \delta \) and \( A_2 \beta \) but not the \( A_3 \) adenosine receptor. *J. Pharmacol. Exp. Ther.* (2006) 317:172-180.

72. MONTESINOS MC, DESAI A, DELANO D et al.; Adenosine \( A_2 \delta \) or \( A_3 \) receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. *Arthritis Rheum.* (2003) 48:240-247.

73. SZABO C, SCOTT GS, VIRAG L et al.: Suppression of macrophage inflammatory protein (MIP)-1\( \beta \) production and collagen-induced arthritis by adenosine receptor agonists. *Br. J. Pharmacol.* (1998) 125:379-387.

74. MADI L, COHEN S, OCHAYIN A, BAR-YEHUDA S, BARER F, FISHMAN P: Overexpression of \( A_3 \) adenosine receptor in peripheral blood mononuclear cells in rheumatoid arthritis: involvement of NF-\( \kappa B \) in mediating receptor level. *J. Rheumatol.* (2007) 34:20-24.

75. BAHARAV E, BAR-YEHUSA S, MADI L et al.; Antiinflammatory effect of \( A_3 \) adenosine receptor agonists in murine autoimmune arthritis models. *J. Rheumatol.* (2005) 32:469-476.

76. PETROVA N, EDMONDS M: Emerging drugs for diabetic foot ulcers. *Expert Opin. Emerg. Drugs* (2006) 11:709-724.

77. LIPSKY PE: A modest proposal. *Nat. Clin. Pract. Rheumatol.* (2006) 2:343.

78. KOHNO Y, SEI Y, KOSHIHA M, KIM HO, JACOBSON KA: Induction of apoptosis in HL-60 human promyelocytic leukemia cells by adenosine \( A_3 \) receptor agonists. *Biochem. Biophys. Res. Commun.* (1996) 219:904-910.

79. GAO Z, LI BS, DAY YJ, LINDEN J; \( A_3 \) adenosine receptor activation triggers phosphorylation of protein kinase B and protects rat basophilic leukemia 2H3 mast cells from apoptosis. *Mol. Pharmacol.* (2001) 59:76-82.

80. LU J, PIERRON A, RAVID K: An adenosine analogue, IB-MECA, down-regulates estrogen receptor \( \alpha \) and suppresses human breast cancer cell proliferation. *Cancer Res.* (2003) 63:6413-6423.

81. KIM SG, RAVI G, HOFFMANN C et al.; \( p53 \)-independent induction of Fas and apoptosis in leukemic cells by an adenosine derivative, CI-IB-MECA. *Biochem. Pharmacol.* (2002) 63:871-880.

82. LEE EJ, MIN HY, CHUNG HJ et al.: A novel adenosine analog, thio-CI-IB-MECA, induces G0/G1 cell cycle arrest and apoptosis in human promyelocytic leukemia HL-60 cells. *Biochem. Pharmacol.* (2005) 70:918-924.

83. MERIGHI S, MIRANDOLA P, VARANI K et al.; A glance at adenosine receptors: novel target for antitumor therapy. *Pharmacol. Ther.* (2003) 100:31-48.

84. MERIGHI S, MIRANDOLA P, MILANI D et al.; Adenosine receptors as mediators of cell proliferation and cancer death of cultured human melanoma cells. *J. Invest. Dermatol.* (2002) 119:923-933.

85. MERIGHI S, BENINI A, MIRANDOLA P et al.; \( A_3 \) adenosine receptor activation inhibits cell proliferation via phosphatidylinositol 3-kinase (PI3K)/AKT-dependent inhibition of the extracellular signal-regulated kinase (ERK)1/2 phosphorylation in A375 human melanoma cells. *J. Biol. Chem.* (2005) 280:19516-19526.

86. GESSI S, MERIGHI S, VARANI K et al.; Adenosine receptors in colon carcinoma tissues and colon tumoral cell lines: focus on the \( A_3 \) adenosine subtype. *J. Cell Physiol.* (2007) 211:826-836.

87. GESSI S, CATTABRIGA E, AVITABLE A et al.; Elevated expression of \( A_3 \) adenosine receptors in human colorectal cancer is reflected in peripheral blood cells. *Clin. Cancer Res.* (2004) 10:5895-5901.

88. FISHMAN P, BAR-YEHUSA S, VAGMAN L; Adenosine and other low molecular weight factors released by muscle cells inhibit tumor cell growth. *Cancer Res.* (1998) 58:3181-3187.

89. FISHMAN P, BAR-YEHUSA S, OHANA G et al.; Adenosine acts as an inhibitor of lymphoma cell growth: a major role for the \( A_3 \) adenosine receptor. *Eur. J. Cancer* (2000) 36:1452-1458.

90. FISHMAN P, MADI L, BAR-YEHUSA S, BARER F, DEL VALLE L, KHALILI K; Evidence for involvement of Wnt signaling pathway in IB-MECA-mediated suppression of melanoma cells. *Onco gene* (2002) 21:4060-4064.

91. OHANA G, BAR-YEHUSA S, ARICH A et al.; Inhibition of primary colon carcinoma growth and liver metastasis by the \( A_3 \) adenosine receptor agonist CF101. *Br. J. Cancer* (2003) 89:1552-1558.

92. FISHMAN P, BAR-YEHUSA S, OHANA G et al.; An agonist to the \( A_3 \) adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3 \( \beta \) and NF-\( \kappa B \). *Onco gene* (2004) 23:2465-2471.

93. BAR-YEHUSA S, MADI L, SILBERMAN D, GERY S, SHKAPENUK M, FISHMAN P; CF101, an agonist to the \( A_3 \) adenosine receptor, enhances the chemotherapeutic effect of 5-fluorouracil in a colon carcinoma murine model. *Neoplasia* (2005) 7:85-90.

94. BAR-YEHUSA S, MADI L, BARAK D et al.; Agonists to the \( A_3 \) adenosine receptor induce G-CSF production via NF-\( \kappa B \) activation: a new class of myeloprotective agents. *Exp. Hematol.* (2002) 30:1390-1398.

95. MADI L, OCHIAION A, RATH-WOLFSON L et al.; The \( A_3 \) adenosine receptor is highly expressed in tumor versus normal cells: potential target for tumor growth inhibition. *Clin. Cancer Res.* (2004) 10:4472-4479.

96. ELMENHORST D, MEYER PT, WINZ OH et al.; Sleep deprivation increases A1 adenosine receptor binding in the human brain: a positron emission tomography study. *J. Neurosci.* (2007) 27:2410-2415.

97. BAR-YEHUSA S, OCHIAION A, JACOBSON K et al.; CF502 targets the \( A_3 \) adenosine receptor to induce anti-inflammatory effect via down-regulation of the NF-\( \kappa B \) signaling pathway. Abstract for the 2007 ACR Meeting.
Emerging adenosine receptor agonists

98. TCHILIBON S, JOSHI BV, KIM SK et al.: (N)-methanocarba 2,N6-disubstituted adenine nucleosides as highly potent and selective A<sub>3</sub> adenosine receptor agonists. *J. Med. Chem.* (2005) 48:1745-1758.

**Patents**

101. BAYER AKTIENGESELLSCHAFT: WO0125210 (2001).
102. BAYER AKTIENGESELLSCHAFT: WO03008384 (2003).
103. KING PHARMACEUTICALS: US6358964 (2002).
104. ADERIS PHARMACEUTICALS: WO025545 (2005).
105. BIOVITRUM: WO2005084653 (2005).

**Websites**

201. http://www.clinicaltrials.gov/ct/show/NCT00040001?order=1
ADERIS PHARMACEUTICALS: Safety and efficacy study of an A<sub>1</sub>-adenosine receptor agonist to slow heart rate in atrial fibrillation (2005).

202. http://www.clinicaltrials.gov/ct/show/NCT00376454?order=1
GlaxoSmithKline: The study of GW493838, an adenosine A<sub>1</sub> agonist, in peripheral neuropathic pain (2006).

203. http://www.clinicaltrials.gov/ct/show/NCT00452777?order=1
BIOVITRUM: Efficacy and Tolerability of Novel A<sub>2A</sub> Agonist in Treatment of Diabetic Neuropathic Pain (2007).

204. http://www.clinicaltrials.gov/ct/show/NCT00298636?order=1
XSIRA PHARMACEUTICALS: Dose-response of adenosine for perioperative pain (2006).

205. http://www.clinicaltrials.gov/ct/show/NCT00162084?order=3
Bristol-Myers Squibb: A study to examine MPI SPECT imaging with BMS068645 and adenosine compared to coronary angiography (2007).

206. http://www.clinicaltrials.gov/ct/show/NCT00312364?order=1
King Pharmaceuticals: Safety and efficacy study of MRE0094 to treat large, single or multiple, chronic, neuropathic, diabetic foot ulcers (2007).

**Affiliation**

Zhan-Guo Gao<sup>1</sup> & Kenneth A Jacobson<sup>2</sup>
<sup>1</sup>Author for correspondence
<sup>2</sup>Staff Scientist,
NIDDK, National Institutes of Health,
Laboratory of Bioorganic Chemistry,
Bldg. 8A, Room B1A-23, 9000 Rockville Pike,
Bethesda, Maryland 20892-0810, USA
Fax: +1 301 480 8422;
E-mail: zg21o@nih.gov
<sup>2</sup>Chief, Molecular Recognition Section,
NIDDK, National Institutes of Health,
Laboratory of Bioorganic Chemistry,
Bldg. 8A, Room B1A-19, 9000 Rockville Pike,
Bethesda, Maryland 20892-0810, USA
Fax: +1 301 480 8422;
E-mail: kajacobs@helix.nih.gov